Mostrando 7 resultados de: 7
Filtros aplicados
Área temáticas
Enfermedades(4)
Farmacología y terapéutica(4)
Fisiología humana(4)
Salud y seguridad personal(4)
Medicina y salud(1)
Ciprofibrate treatment decreases non-high density lipoprotein cholesterol and triglycerides and increases high density lipoprotein cholesterol in patients with frederickson type IV dyslipidemia phenotype
Conference ObjectAbstract: OBJECTIVE: The combination of hypertriglyceridemia and low high density lipoprotein (HDL) cholesteroPalabras claves:Ciprofibrate, Frederickson's type IV dyslipidemia, High density lipoprotein cholesterol, Hyperlipidemia, Low density lipoprotein cholesterol, Non-high density lipoprotein cholesterol, TriglyceridesAutores:Arráiz N., Bermúdez-Arias F., Cano-Peñaloza R., Cano-Ponce C., Contreras F., de Bravo M.C., De Diaz A.A., De Pirela N.L., Israili Z.H., Leal-Gonzalez E., Lemus-Antepaz M., Mengual-Moreno E., Puche-Medina G., Reyna-Villazmil N., Souki-Rincón A., Valasco M., Valmore BermúdezFuentes:scopusAn elevated level of physical activity is associated with normal lipoprotein(a) levels in individuals from Maracaibo, Venezuela
ArticleAbstract: Coronary artery disease is the main cause of death worldwide. Lipoprotein(a) [Lp(a)], is an independPalabras claves:Cardiovascular Risk, Lifestyle, lipoprotein(a), Physical activityAutores:Acosta L., Añez-Ramos R., Aparicio D., Arráiz N., Cano R.A., Cano-Ponce C., Colmenares C., Faria J., Finol F., Mengual-Moreno E., Peñaranda L., Pineda C., Rodriguez D., Rojas E.R., Rojas-Quintero J., Sanchez W., Sorell L.T., Toledo A.C., Urribarí J., Valmore Bermúdez, Velasco M.Fuentes:scopusOat-derived β-glucan significantly improves HDLC and diminishes LDLC and non-HDL cholesterol in overweight individuals with mild hypercholesterolemia
Conference ObjectAbstract: OBJECTIVE: To investigate the effect of bread formulated with 6 g of β-glucan (oat soluble fiber) onPalabras claves:HDL cholesterol, LDL cholesterol, LDL cholesterol/HDL cholesterol ratio, Non-HDL cholesterol, Oat soluble fiber, Total cholesterol/HDL cholesterol ratio, β-glucanAutores:Arias N., Arráiz N., Cano-Ponce C., Hernández-Hernandez R., Inglett G.E., Israili Z.H., Leal-Gonzalez E., Mengual-Moreno E., Reyna-Villasmil N., Souki-Rincón A., Valasco M., Valmore BermúdezFuentes:scopusHomeostasis model assessment (HOMA) as surrogate insulinization criteria in patients with type 2 diabetes
ArticleAbstract: Type 2 diabetes mellitus is a metabolic disorder that results from defects in both insulin secretionPalabras claves:Free fatty acids, HOMA, Insulin, Insulin Resistance, Type 2 Diabetes mellitusAutores:Acosta K., Aparicio D., Arráiz N., Bermúdez F.A., Briceño C., Bustamante M., Cabrera M., Cano R.A., Cano-Ponce C., Gómez J., Hernández-Hernandez R., Joselyn Zula, Leal E.M., Manuel V., Mengual-Moreno E., Rodriguez M., Valdelamar L., Valmore BermúdezFuentes:googlescopusIncreased levels of lipoprotein (a) are related to family risk factors of cardiovascular disease in children and adolescents from Maracaibo, Venezuela
ArticleAbstract: The aims of this study were to determine Lipoprotein (a) [Lp(a)] concentrations in a sample of subjePalabras claves:adolescents, CHILDREN, CVD risk factors, Family history, Lipoprotein (a)Autores:Almarza J., Cano-Peñaloza R., Cano-Ponce C., García-Camacho D., Hernández-Hernandez R., Israili Z.H., Mengual-Moreno E., Sorell L.T., Souki-Rincón A., Torres D., Urdaneta J., Valmore Bermúdez, Velasco M.Fuentes:scopusLipoprotein(a): From molecules to therapeutics
ReviewAbstract: Lipoprotein (a) [Lp(a)] was discovered by Kare Berg in 1963 from the study of low-density lipoproteiPalabras claves:Atherogenesis, Cardiovascular disease, Hyperlipoproteinemia(a), lipoprotein(a), therapeuticsAutores:Amell A., Aparicio D., Arráiz N., Cabrera M., Canelón R., Cano R.A., Cano-Ponce C., Faria J., Gotera D., Guerra-Torres X.E., Mengual-Moreno E., Reyna-Villasmil N., Rojas E.R., Sorell L.T., Valmore Bermúdez, Velasco M.Fuentes:scopusThe maracaibo city metabolic syndrome prevalence study: Design and scope
ArticleAbstract: The metabolic syndrome (MS) is a conglomerate of interrelated risk factors-including obesity, atheroPalabras claves:Blood pressure, Cardiovascular Risk Factors, cross-sectional studies, dyslipidemia, Metabolic syndromeAutores:Amell A., Arráiz N., Cabrera M., Cano J.R., Cano R.A., Cano-Ponce C., Finol F., González J., Luti Y., Marcano R.P., Mengual-Moreno E., Miranda J.L., Montes J., Reyna-Villasmil N., Rojas E.R., Sánchez D., Sanchez W., Valmore Bermúdez, Vega L., Velasco M.Fuentes:scopus